Beactica Extends Fragment-Based Discovery Research Services Agreement
News Nov 29, 2012
Beactica has announced that it has added a project under its ongoing research services agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV.
Under the research services agreement, Beactica will use its proprietary drug discovery platform Sprint™ to identify novel allosteric modulators targeting undisclosed central nervous system (CNS) proteins of therapeutic interest to Janssen. Financial terms of the agreement were not disclosed.
“We are pleased to extend our collaboration with Janssen and look forward to further supporting their efforts to discover innovative medicines” said Beactica CEO, Dr Per Källblad.
Dr Källblad continued, “The extension of our relationship testifies to the ability of our Sprint™ platform to generate novel, high-quality medicinal chemistry starting points against challenging drug targets”.
Beactica initiated their first research services project with Janssen in early 2011.
Symmetry-breaking Method Opens Way for Bioactive CompoundsNews
EPFL chemists have developed a new catalytic method for symmetry breaking. Published in Angewandte Chemie, the method can help synthesize important building blocks for bioactive compounds such as anticancer drugs.READ MORE
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE